Last SFr.9.80 CHF
Change Today 0.00 / 0.00%
Volume 0.0
WBIO On Other Exchanges
Symbol
Exchange
Berne
As of 11:35 AM 03/27/14 All times are local (Market data is delayed by at least 15 minutes).

wockhardt bio ag-br (WBIO) Key Developments

Forest Labs Sues Sun Pharma Global FZE, Teva Pharmaceuticals USA, Inc. and Wockhardt Bio AG for Infringement of NAMENDA XR Patents

Forest Laboratories, Inc. and Forest Laboratories Holdings Ltd. Said Friday that Forest, Merz Pharma GmbH & Co. KgaA and Adamas Pharmaceuticals, Inc. have jointly filed a lawsuit in the U.S. District Court for the District of Delaware against several companies for infringement of some or all of U.S. Patent Nos. 5,061,703; 8,039,009; 8,168,209; 8,173,708; 8,283,379; 8,329,752; 8,362,085; and 8,598,233, which relate to Forest's NAMENDA XR product. Forest licenses the '703 patent, which expires in April 2015, from Merz, and the '209, '708, '379, '752, '085 and '233 patents, which expire in November 2025, from Adamas. Forest owns the '009 patent, which expires in March 2029. The defendants named in the lawsuit include Sun Pharma Global FZE, Teva Pharmaceuticals USA, Inc., Wockhardt Bio AG, and related companies and subsidiaries. Forest received notification from those companies that they had filed Abbreviated New Drug Applications with Paragraph IV certifications seeking approval to market generic versions of NAMENDA XR before the expiration of some or all of the Patents. The lawsuit was commenced before the expiration of forty-five days from the date of receipt of each notification letter, which triggered an automatic stay of approval of the applicable ANDAs that expires no earlier than June 2016.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WBIO:SW SFr.9.80 CHF 0.00

WBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for WBIO.
View Industry Companies
 

Industry Analysis

WBIO

Industry Average

Valuation WBIO Industry Range
No financial data is available for WBIO.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WOCKHARDT BIO AG-BR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.